



Amicus Blue

Therapeutics and Cell Collection

The Amicus Blue apheresis system provides a single solution to support your patients' individual needs.

The precision design and time tested technology of the Amicus Separator are the foundation that provides the flexibility to support various therapeutic and collection protocols.


Options include:

- Therapeutic Plasma Exchange
- Red Blood Cell Exchange
- Mononuclear Cell Collection
- Platelet Collection, and
- Extracorporeal Photopheresis

One Solution for Complete Care



Your New Choice in Therapy



Contact your local Fresenius Kabi representative to learn more about Amicus Blue or visit us online at www.amicusblue-fresenius-kabi.com, or email us at amicus@fresenius-kabi.com.



Fresenius Kabi AG
61346 Bad Homburg
Germany

Phone: +49 61 72 608-0
www.fresenius-kabi.com

One Solution for Complete Care



TPE

Therapeutic Plasma Exchange

High plasma removal efficiency, accurate fluid balance control with real-time volume measurement



RBCx

Red Blood Cell Exchange

Precision red cell removal for Exchange, Depletion/Exchange, and Depletion procedures



Amicus Blue

Platelets



Platelet Collections

High efficiency platelet collection, options for concurrent plasma and RBC collection, and automatic PAS capability

ECP



Extracorporeal Photopheresis

The ECP protocol is an expanded indication for the Amicus Blue System, utilizing Amicus MNC collection technology and the Phelix Photoactivation Device

MNC



Mononuclear Cell Collection

High MNC collection efficiency with low platelet loss, flexible controls allow tailoring of MNC settings for targeted cell content based upon clinical need

Extracorporeal Photopheresis (ECP)

The Amicus Blue System for ECP consists of the Amicus Separator, the Phelix Photoactivation Device, and a single-use disposable kit to create an online, closed system to perform photopheresis.

Performance and Safety

The Phelix Photoactivation Device continuously monitors the intensity of UVA light, temperature of the collected MNCs and agitation to ensure delivery of the target UVA light dose.

Bi-directional communication between the Amicus and Phelix allow for easy control of the system from the Amicus device. Photoactivation progress and results can be monitored and viewed from the Amicus touchscreen user interface. Amicus reinfuses the treated cells back to the patient.

NOTE: The Amicus ECP System has obtained CE mark approval for the indication of CTCL in the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL) that is unresponsive to other forms of treatment.

